Abstract:MicroRNAs (miRNAs or miRs), including miR-34a, have been shown to regulate nuclear receptor, drug-metabolizing enzyme, and transporter gene expression in various cell model systems. However, to what degree miRNAs affect pharmacokinetics (PK) at the systemic level remains unknown. In addition, miR-34a replacement therapy represents a new cancer treatment strategy, although it is unknown whether miR-34a therapeutic agents could elicit any drug–drug interactions. To address this question, we refined a practical single-mouse PK approach and investigated the effects of a bioengineered miR-34a agent on the PK of several cytochrome P450 probe drugs (midazolam, dextromethorphan, phenacetin, diclofenac, and chlorzoxazone) administered as a cocktail. This approach involves manual serial blood microsampling from a single mouse and requires a sensitive liquid chromatography–tandem mass spectrometry assay, which was able to illustrate the sharp changes in midazolam PK by ketoconazole and pregnenolone 16α-carbonitrile as well as phenacetin PK by α-naphthoflavone and 3-methylcholanthrene. Surprisingly, 3-methylcholanthrene also decreased systemic exposure to midazolam, whereas both pregnenolone 16α-carbonitrile and 3-methylcholanthrene largely reduced the exposure to dextromethorphan, diclofenac, and chlorzoxazone. Finally, the biologic miR-34a agent had no significant effects on the PK of cocktail drugs but caused a marginal (45%–48%) increase in systemic exposure to midazolam, phenacetin, and dextromethorphan in mice. In vitro validation of these data suggested that miR-34a slightly attenuated intrinsic clearance of dextromethorphan. These findings from single-mouse PK and corresponding mouse liver microsome models suggest that miR-34a might have minor or no effects on the PK of coadministered cytochrome P450–metabolized drugs.

Pharmacokinetics of Plant Derived miRNAs Following Intravenous Administration

Methodological framework for functional characterization of plant microRNAs.

A Timely Review of Cross-Kingdom Regulation of Plant-Derived MicroRNAs

Assessing the survival of exogenous plant microRNA in mice.

Real-time quantitative PCR and droplet digital PCR for plant miRNAs in mammalian blood provide little evidence for general uptake of dietary miRNAs

MicroRNAs in Medicinal Plants

Bioavailability of transgenic microRNAs in genetically modified plants

Effective Detection and Quantification of Dietetically Absorbed Plant Micrornas in Human Plasma.

Cross-kingdom regulation by plant-derived miRNAs in mammalian systems

The Stability of Medicinal Plant microRNAs in the Herb Preparation Process

Cross-kingdom inhibition of breast cancer growth by plant miR159

Large-scale identification of extracellular plant miRNAs in mammals implicates their dietary intake

Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA

Anomalous uptake and circulatory characteristics of the plant-based small RNA MIR2911

Plant-derived miR166a-3p packaged into exosomes to cross-kingdom inhibit mammary cell proliferation and promote apoptosis by targeting APLNR gene

An improved method to quantitate mature plant microRNA in biological matrices using modified periodate treatment and inclusion of internal controls

Effects of Microrna-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice

Advances in Bioactivity of MicroRNAs of Plant-Derived Exosome-Like Nanoparticles and Milk-Derived Extracellular Vesicles.

Cross-kingdom regulation of plant microRNAs: potential application in crop improvement and human disease therapeutics

MicroRNAs from edible plants reach the human gastrointestinal tract and may act as potential regulators of gene expression

Cross-kingdom regulation by dietary plant miRNAs: an evidence-based review with recent updates